Related Experiment Video
Updated: May 26, 2025
08:16
Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
Published on: March 15, 2024
1.4K
Diabetes Technology Trends: A Review of the Latest Innovations
Erika L Lundgrin1,2,3, Clare A Kelly1,2, Natalie Bellini1,2
1Diabetes and Metabolic Care Center, University Hospitals, Cleveland, OH 44106, USA.
The Journal of Clinical Endocrinology and Metabolism
|February 25, 2025
Summary
Recent diabetes management technologies, including continuous glucose monitors and automated insulin delivery, have improved glucose control and quality of life for patients with type 1 and type 2 diabetes.
Area of Science:
- Endocrinology
- Medical Technology
- Digital Health
Background:
- Diabetes management has seen rapid growth in technological tools like continuous glucose monitors and automated insulin delivery systems.
- Increased availability of these devices is driving their adoption for better diabetes care.
- This review focuses on recent innovations in the United States aimed at improving patient outcomes.
Purpose of the Study:
- To review recent technological innovations in diabetes management available in the U.S.
- To highlight advancements that improve patient outcomes and quality of life.
- To inform healthcare providers and patients about the evolving landscape of diabetes technology.
Main Methods:
- A systematic literature search was performed across major databases (Medline, PubMed, ScienceDirect, Embase, Cochrane Library).
- The search focused on peer-reviewed articles published between 2014 and 2024.
- Studies specifically examining technology-assisted treatment in diabetes care were included.
Main Results:
- Diabetes technology has substantially reduced the burden of glucose monitoring and insulin delivery.
- Clinical trials demonstrate improved accuracy and glycemic outcomes with these advanced technologies.
- Use of diabetes technologies is linked to enhanced patient self-efficacy and improved quality of life for individuals with type 1 and type 2 diabetes.
Conclusions:
- Diabetes technology significantly enhances glycemic control, patient satisfaction, and overall quality of life.
- Assessing the role of technology is crucial for both type 1 and type 2 diabetes management.
- Individualized treatment goals are essential when integrating technology into diabetes care.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
01:15Diabetes: Management and Pharmacotherapy
227
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
227
01:22Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
01:15Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
01:06Oral Hypoglycemic Agents: Glinides
131
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
131
01:24Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291